Champions Oncology (CSBR) Net Cash Flow (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Net Cash Flow of -$2.3 million for Q2 2026, down 134.25% year-over-year from $6.6 million in Q2 2025, and down 62.35% quarter-over-quarter from -$1.4 million in Q1 2026.
Champions Oncology (CSBR) Net Cash Flow (2010 - 2026) Analysis & Trends
Champions Oncology's Net Cash Flow history runs 17 years deep, the most recent figure standing at -$2.3 million for Q2 2026.
- In Q2 2026, Net Cash Flow fell 134.25% year-over-year to -$2.3 million; the TTM figure through Apr 2026 stood at -$4.9 million (down 168.55% YoY), while the FY2026 annual figure was -$4.9 million, down 168.55% from the prior year.
- Net Cash Flow for Q2 2026 stood at -$2.3 million, down from -$1.4 million in the prior quarter.
- The five-year high for Net Cash Flow was $6.6 million in Q2 2025, with the low at -$5.2 million in Q3 2023.
- The 5-year median for Net Cash Flow is $68000.0 (2024), against an average of $5055.6.
- Peak annual rise in Net Cash Flow reached 455.84% in 2025, while the deepest fall reached 1210.87% in 2025.
- Champions Oncology's Net Cash Flow stood at $2.8 million in 2022, then plunged by 76.73% to $644000.0 in 2023, then plunged by 121.43% to -$138000.0 in 2024, then sank by 1210.87% to -$1.8 million in 2025, then dropped by 24.65% to -$2.3 million in 2026.
- Business Quant data shows CSBR's Net Cash Flow at -$2.3 million in Q2 2026, -$1.4 million in Q1 2026, and -$1.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | -2.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -2.26 Mn |
| Apr 30, 2026 | -2.26 Mn |
| Jan 31, 2026 | -1.39 Mn |
| Jan 31, 2026 | -1.39 Mn |
| Oct 31, 2025 | -1.81 Mn |
| Oct 31, 2025 | -1.81 Mn |
| Jul 31, 2025 | 540,000.00 |
| Jul 31, 2025 | 540,000.00 |
| Apr 30, 2025 | 6.58 Mn |
| Apr 30, 2025 | 6.58 Mn |
| Jan 31, 2025 | 448,000.00 |
| Jan 31, 2025 | 448,000.00 |
| Oct 31, 2024 | -138,000.00 |
| Oct 31, 2024 | -138,000.00 |
| Jul 31, 2024 | 274,000.00 |
| Jul 31, 2024 | 274,000.00 |
| Apr 30, 2024 | -1.85 Mn |
| Apr 30, 2024 | -1.85 Mn |
| Jan 31, 2024 | -1.05 Mn |
| Jan 31, 2024 | -1.05 Mn |